Journal of the Japanese Society of Intensive Care Medicine, Год журнала: 2024, Номер 31(6), С. 533 - 535
Опубликована: Окт. 31, 2024
Язык: Английский
The Lancet. Gastroenterology & hepatology, Год журнала: 2024, Номер 9(8), С. 745 - 757
Опубликована: Май 13, 2024
Язык: Английский
Процитировано
23
European Journal of Clinical Microbiology & Infectious Diseases, Год журнала: 2025, Номер unknown
Опубликована: Янв. 22, 2025
Abstract Purpose To evaluate diagnostic performance of four methods for rapid determination methicillin resistance in S. aureus positive blood cultures (BCs). Methods Clinical and spiked BCs were subjected to the evaluation following protocols: a. Eazyplex ® MRSA Plus loop‐mediated isothermal amplification (LAMP) assay directly from BC fluid; b. MALDI-TOF MS subtyping on pellet extracted with Rapid Sepsityper protocol 4-h short-term subculture; c. Clearview™ Culture Colony PBP2a SA immunochromatography d. EUCAST RAST cefoxitin screen test performed including reading times at 4-h, 6-h 16–20-h. Results plus exhibited best performance, showing 100% sensitivity, specificity, predictive value, negative followed by Clearview screen. showed lowest accuracy (59.8 65.7% subculture, respectively). In detail, sensitivity specificity ranged 24.3% 20.4% 88.9% 98.3% protocols respectively. Conclusions The immunochromatographic can provide reliable results within 1 h start processing. MALDI TOF unacceptable performing analysis pellets, while its depends prevalence PSM-positive strains. RAST, based disc diffusion, excellent a time-to-result least 4 h.
Язык: Английский
Процитировано
1
Chemical Engineering Journal, Год журнала: 2025, Номер unknown, С. 160268 - 160268
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
1
Clinical Medicine, Год журнала: 2024, Номер 24(6), С. 100265 - 100265
Опубликована: Ноя. 1, 2024
Staphylococcus aureus bacteraemia (SAB) is a multi-system disease associated with 20-25% mortality in the UK setting. Many patients SAB are admitted acutely unwell and treated by general physician. This review summarises key management steps that physician needs to be aware of when treating SAB. Successful relies on appropriate empirical definitive antimicrobial therapy, effective source control, accurate risk stratification timely identification metastatic foci infection, as well exclusion infective endocarditis, which can present up 10%
Язык: Английский
Процитировано
4
Scientific Reports, Год журнала: 2025, Номер 15(1)
Опубликована: Янв. 2, 2025
Язык: Английский
Процитировано
0
Microorganisms, Год журнала: 2025, Номер 13(1), С. 101 - 101
Опубликована: Янв. 7, 2025
Vancomycin-intermediate Staphylococcus aureus (VISA) is a multi-drug-resistant pathogen of significant clinical concern. Various S. strains can cause infections, from skin and soft tissue infections to life-threatening conditions such as bacteremia pneumonia. VISA particularly bacteremia, are associated with high mortality rates, 34% patients succumbing within 30 days. This study aimed develop predictive models for (including hVISA) outcomes using data mining techniques, potentially improving patient management therapy selection. We focused on three endpoints in receiving traditional vancomycin therapy: persistence after 7 days, mortality. Our analysis incorporated 29 risk factors bacteremia. The resulting demonstrated accuracy, 82.0-86.6% accuracy 7-day blood cultures 53.4-69.2% 30-day These findings suggest that techniques effectively predict settings. developed have the potential be applied prospectively hospital settings, aiding stratification informing treatment decisions. Further validation through prospective studies warranted confirm utility these tools managing infections.
Язык: Английский
Процитировано
0
Infection, Год журнала: 2025, Номер unknown
Опубликована: Янв. 27, 2025
Abstract Purpose To analyze the associations between adherence to quality indicators (QIs) in treatment of bloodstream infections caused by methicillin-susceptible Staphylococcus (S.) aureus (MSSA) and in-hospital mortality. Methods A retrospective observational study was conducted patients admitted 2019 2023 Hospital St. Georg Leipzig, Germany, with at least one positive blood culture for S. . Ten QIs were categorized into four groups based on results, echocardiography, antibiotic treatment, other parameters such as infectious disease (ID) specialist consultation. Propensity score (PS) matching used compare mortality MSSA treated flucloxacillin those cefazolin. Multivariate Cox regression analysis performed determine risk factors associated Results Of 637 infections, 495 infection (77.8%) included study. After introduction mandatory ID consultation 2020, median QI increased 9 out a maximum 10 points significantly higher surviving cases than fatal subsequent years. There non-significant decrease from (28.8%) (22.7%) ( p = 0.432). Based PS matching, cefazolin had favorable hazard ratio 0.44 (95% CI 0.28–0.71; < 0.001) The results multivariate showed survival rate who received QI-based management, including transesophageal echocardiography therapy initiated within 24 h. Conclusions is better improvement measures. Targeted cefazolin, early initiation therapy, antimicrobial protocols rates our setting.
Язык: Английский
Процитировано
0
Enfermedades Infecciosas y Microbiología Clínica, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0
Journal of Microbiology Immunology and Infection, Год журнала: 2025, Номер unknown
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
0
Expert Review of Anti-infective Therapy, Год журнала: 2025, Номер unknown
Опубликована: Март 31, 2025
Bloodstream infections (BSIs) caused by Staphylococcus aureus are common worldwide, representing one of the most relevant issues in clinical infectious diseases practice. In particular, BSIs methicillin-resistant S. (MRSA-BSI) still today a challenge since mortality burden remains elevated although decades research. The following topics regarding MRSA-BSI were reviewed and discussed resorting to best available evidence retrieved from PubMed/MEDLINE up October 2024: i) epidemiology; ii) microbiology; iii) classification, with focus on complicated not forms; iv) structured approach patient; v) pharmacokinetics pharmacodynamics main antimicrobial options; vi) controversies therapeutic approach. Despite ongoing efforts better stratify manage MRSA-BSI, there is no universally accepted classification system accurately distinguishing between uncomplicated/low risk complicated/high forms. Biomarkers such as interleukin(IL)-10 hold promise order enable more precise stratification, premise for an appropriate treatment plan. There theoretical rationale implementing combination therapy including beta-lactam agent upfront, especially patients considered at higher unfavorable outcomes, but further data necessary, same applies newer adjuvants. Novel microbiological techniques may help guiding duration.
Язык: Английский
Процитировано
0